-+ 0.00%
-+ 0.00%
-+ 0.00%
Gain Therapeutics Reports Stable Motor Scores After 12 Months in Rexaceract Phase 1b Study
Share
Listen to the news
Gain Therapeutics Reports Stable Motor Scores After 12 Months in Rexaceract Phase 1b Study
  • Gain Therapeutics presented Phase 1b rexaceract results in Parkinson's disease at the 31st IAPRD World Congress.
  • Motor scores remained stable without overall disease progression among 13 evaluable participants completing 12 months of daily oral treatment.
  • Rexaceract was generally well tolerated, with no new safety concerns during the nine-month extension.
  • Additional biomarker findings are expected by year-end 2026 to further assess disease-specific responses.
  • Presented preclinical results showed GT-04686 improved motor and nonmotor function; selection of an initial therapeutic indication is expected by fourth-quarter 2026's end.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611171615PRIMZONEFULLFEED9879861) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending